# Thoracic Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Yul Brynner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML020-SYN-TD
- Date: 1983-09-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Leah Morrow, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Simon Achterberg, MD

## Reason for consultation

Left upper lobe mass invading the mediastinum with mediastinal nodes and left vocal fold paralysis in a 63-year-old former heavy smoker. Please establish the diagnosis and stage, direct biomarker testing, and advise on first-line treatment. **S**

## History

Mr. Brynner is seen at the request of Dr. Achterberg two weeks after he presented with six weeks of a weak, breathy voice. He is a stage actor and singer leading a touring production, which he has paused. He smoked about three packs a day from the age of 12 and quit 12 years ago. He has a mild morning cough, no hemoptysis, no chest, bone, or back pain, no headache, and no neurological symptoms, and his weight is steady after a small loss before presentation. He is fully active offstage but tires by evening. He has no autoimmune disease, organ transplant, or use of corticosteroids or other immunosuppressants. He wants the facts in full and wants to return to the stage. **S**

## Examination

| System | Finding |
|---|---|
| General | Upright and composed; ECOG 1; weight 72.0 kg |
| Voice | Breathy, low-volume voice |
| Lymph nodes | No supraclavicular or cervical nodes |
| Lungs | Slightly reduced breath sounds at the left apex |
| Spine and pelvis | No tenderness over T10, the ribs, or the right iliac crest |
| Neurological | Normal strength, sensation, and gait |

BP 128/78 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 96% on room air; weight 72 kg; BMI 22.7 kg/m². All vital signs are synthetic.

## Data reviewed

Laryngoscopy; CT of the chest, abdomen, and pelvis; FDG PET-CT and brain MRI eleven days ago; endobronchial ultrasound needle aspiration six days ago with cytology, immunohistochemistry, and PD-L1; plasma cell-free DNA sequencing; intake laboratory results. ESAS total symptom distress score: 18. All results are synthetic.

## Assessment

1. **Adenocarcinoma of the left upper lobe, stage IVB (cT4 N2 M1c)** (C34.12). Adenocarcinoma, TTF-1 and napsin A positive, from subcarinal and 4L nodes. The primary invades the mediastinum (T4), the aortopulmonary window and subcarinal nodes are involved (N2), and PET-CT shows avid lytic lesions at T10, the right ilium, and the left sixth rib (M1c, stage IVB). Several typical avid lytic lesions do not need biopsy, because confirming one would not change treatment. The brain MRI is clear. The tumor is not resectable and not curable with surgery or chemoradiation; treatment aims at control, symptom relief, and time. **S**
2. **Biomarkers**. PD-L1 (22C3) tumor proportion score 70 percent. Plasma testing shows no actionable alteration, but a negative plasma result does not exclude a driver, so tissue sequencing (EGFR, ALK, ROS1, BRAF, KRAS G12C, MET exon 14, RET, NTRK, HER2, NRG1) must be reviewed before an immune checkpoint inhibitor is started: starting one before a targetable driver is found can raise the toxicity of later targeted therapy and gives less benefit. The result is expected within a week, so waiting costs little. **S**
3. **First-line therapy**. If no actionable alteration is found, NCCN lists pembrolizumab alone, or pembrolizumab with carboplatin and pemetrexed, among the preferred first-line options for PD-L1 50 percent or more. With ECOG 1, no visceral crisis, and his wish to keep his energy and voice for the stage, pembrolizumab 200 mg every 3 weeks is recommended, with chemotherapy added at progression. He has no autoimmune or transplant history that would argue against immunotherapy. After the first response scan, 400 mg every 6 weeks would fit touring. **S**
4. **Bone metastases** (C79.51). No pain, fracture, or threatened cord, so no radiation is needed now. A bone-modifying agent reduces skeletal events: zoledronic acid 4 mg every 12 weeks after a dental examination, with calcium and vitamin D. Palliative radiation if a lesion becomes painful or threatens fracture. **S**
5. **Left vocal fold paralysis** (J38.01). Caused by recurrent laryngeal nerve involvement in the aortopulmonary window. Radiation is unlikely to restore nerve function; injection medialization and voice therapy offer the best chance of a stage-worthy voice. **S**

## Recommendations

1. Wait for tissue sequencing, expected within a week; if it shows no actionable alteration, start pembrolizumab 200 mg every 3 weeks.
2. Baseline TSH, free T4, morning cortisol, liver tests, glucose, creatinine, and blood count; then TSH, free T4, liver tests, glucose, creatinine, and blood count before each infusion, with cortisol for fatigue, dizziness, low blood pressure, or low sodium.
3. Give him a written list of warning symptoms (diarrhea, new cough or breathlessness, rash, yellowing, severe fatigue, headache, or dizziness) and the 24-hour oncology telephone line; primary care should call oncology the same day for any of them and should not start corticosteroids without discussion, except in an emergency.
4. Response CT of the chest, abdomen, and pelvis about nine weeks after starting, then every 6 to 12 weeks.
5. Dental examination, then zoledronic acid 4 mg every 12 weeks with calcium and vitamin D; start it with the second cycle so that a first-dose reaction is not confused with an early immune-related event.
6. Early palliative care within the next few weeks, alongside treatment, with symptom and distress screening at every visit.
7. Injection medialization and voice therapy, and a graded return to performing as he chooses, with infusions scheduled around his work.
8. No surgery and no radiation now.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Achterberg the same day; the patient agrees and asked that treatment fit his return to the stage. **S**

## Follow-up

Thoracic oncology will see him next week with the tissue sequencing result to start treatment, and at each cycle. Primary care will continue the CMID lung cancer monitoring, preventive care, and coordination with palliative care. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026), Aether Forge
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021), American Society of Clinical Oncology (Schneider BJ et al., J Clin Oncol 2021;39(36):4073-4126)
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017), American Society of Clinical Oncology (Ferrell BR et al., J Clin Oncol 2017;35(1):96-112)
- NCCN Clinical Practice Guidelines in Oncology: Distress Management (2026), National Comprehensive Cancer Network
